Reading Time: 4 minutesIn 2024, the US Food and Drug Administration (FDA) issued final guidance on the use of decentralized clinical trials (DCTs), Conducting Clinical Trials with Decentralized Elements Guidance for Industry, Investigators, and Other Interested Parties. This new guidance hasn’t introduced radical sweeping changes, but it does acknowledge the DCT practices that have been in place for […]
Article




